CJC-1295 DAC: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Structured Community Data
- โขBased on 130 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Dosing Frequency | Phase I/II clinical studies by ConjuChem examined single and repeated subcutaneous doses. A single 60 mcg/kg dose elevated GH levels 2-10 fold for up to 6 days with sustained IGF-1 elevation for 9-11 days. | Community typically uses fixed 1-2 mg weekly doses regardless of body weight. The once-weekly protocol is based on the extended half-life (6-8 days) demonstrated in clinical data. | moderate The weekly dosing schedule is reasonably aligned with the pharmacokinetic data, though community uses fixed doses rather than weight-based dosing. |
| Continuous vs Pulsatile GH Release | Clinical data showed CJC-1295 DAC produces sustained, continuous GH elevation rather than discrete pulses. This continuous pattern differs from normal physiological GH secretion. | Some community members prefer CJC-1295 without DAC specifically because they believe pulsatile GH release is superior. Others accept the continuous elevation of the DAC version for convenience. | high The debate between continuous (DAC) vs pulsatile (no DAC) GH release is one of the most discussed topics in the GH peptide community. No comparative studies have evaluated long-term body composition outcomes between the two approaches. |
| Standalone vs Combination | Clinical studies examined CJC-1295 DAC as a standalone agent for GH/IGF-1 elevation. | Some users combine CJC-1295 DAC with a GHRP (ipamorelin, GHRP-2), though this is less common than with the no-DAC version due to the already sustained GH elevation. | moderate The pharmacological rationale for adding a GHRP to CJC-1295 DAC is less clear than with the short-acting no-DAC version, given the already elevated baseline GH levels. |
Compare these community approaches with published research findings.
Community Protocols
Weekly Injection Protocol
Popular- Route
- Subcutaneous
- Dose
- 2 mg
- Frequency
- Once weekly
- Duration
- 12-16 weeks
Most common protocol leveraging the extended half-life; single weekly injection for sustained GH/IGF-1 elevation
Twice-Weekly Split Protocol
Common- Route
- Subcutaneous
- Dose
- 1 mg
- Frequency
- Twice weekly
- Duration
- 12-16 weeks
Split weekly dose for more stable blood levels; some users prefer this for reduced side effects
Beginner Titration Protocol
Common- Route
- Subcutaneous
- Dose
- 300-1000 mcg
- Frequency
- Twice weekly, gradually increasing
- Duration
- 12-16 weeks
Start at 300 mcg twice weekly and titrate up based on tolerance; recommended for first-time users
Low-Dose Anti-Aging Protocol
Niche- Route
- Subcutaneous
- Dose
- 1 mg
- Frequency
- Once weekly
- Duration
- Ongoing with periodic breaks
Lower-dose maintenance for general wellness; some users cycle 3 months on, 1 month off
Stacking Patterns
CJC-1295 DAC + Ipamorelin
CommonCombines sustained GHRH-mediated GH elevation with ipamorelin GH pulses for comprehensive growth hormone stimulation
CJC-1295 DAC + BPC-157 + TB-500
NicheComprehensive recovery stack combining GH stimulation with healing peptides for enhanced tissue repair
CJC-1295 DAC + Tesamorelin
NicheDual GHRH approach for maximum GH stimulation; some users alternate rather than combine these two GHRH analogs
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 130+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|CJC-1295 DAC experience reports and weekly dosing discussions(accessed 2026-02-16)
- Reddit r/PeptideResearch|CJC-1295 DAC vs no DAC comparison threads(accessed 2026-02-16)
- Peptides.org|CJC-1295 Dosage Calculator and Chart(accessed 2026-02-16)
- PeptideDosages.com|CJC-1295 DAC 5mg Vial Dosage Protocol(accessed 2026-02-16)
- Muscle and Brawn|CJC-1295 Peptide Guide (benefits, effects, dosage, side effects)(accessed 2026-02-16)
- Alpha Rejuvenation|CJC-1295 Ipamorelin Dosage Guide(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for CJC-1295 DAC. The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
CJC-1295 DAC is one of the most discussed GHRH analogs in the peptide community, valued for its convenience of once-weekly dosing due to its extended half-life. It is often compared against CJC-1295 without DAC (Mod GRF 1-29) in community discussions about optimal GH release patterns.
Understanding Protocol Divergence#
Continuous vs Pulsatile GH Release#
The central debate in the community regarding CJC-1295 DAC is whether continuous GH elevation (DAC version) or pulsatile GH release (no DAC version) produces better long-term outcomes. Physiologically, natural GH secretion is pulsatile, and some community members argue that mimicking this pattern with the no-DAC version is superior. Others note that CJC-1295 DAC does not completely suppress GH pulsatility but rather elevates the overall GH output including pulse amplitude. No comparative studies have directly evaluated these two approaches for body composition or anti-aging outcomes.
Clinical Dose Translation#
Clinical studies used weight-based dosing (30-60 mcg/kg), while the community uses fixed doses of 1-2 mg regardless of body weight. For a 70 kg individual, the clinical dose of 60 mcg/kg would be approximately 4.2 mg, suggesting the standard community dose of 2 mg may be more conservative than the clinical dose range.
Commonly Reported Outcomes#
Community members frequently report the following when using CJC-1295 DAC:
- Sleep quality: Deeper sleep and improved recovery, often noticed within the first 1-2 weeks
- Water retention: Initial water retention that typically subsides after 2-4 weeks
- Body composition: Gradual lean mass gains and fat reduction over 2-4 months
- Skin and hair: Improved skin quality and hair growth over several months
- IGF-1 levels: Users who monitor blood work often report elevated IGF-1 within 2-4 weeks
Important Caveats#
- These are self-reported outcomes without controls or blinding
- CJC-1295 DAC development was suspended after a participant death in clinical trials (the cause was determined to be unrelated to the drug, but trials were not resumed)
- Long-term safety data for chronic use is limited
- Sustained IGF-1 elevation carries theoretical cancer risk that has not been evaluated in long-term studies
Reconstitution and Storage Practices#
Community reconstitution practices for CJC-1295 DAC:
- Reconstitution: 1-2 mL bacteriostatic water per 2 mg vial
- Storage: Reconstituted solution refrigerated at 2-8 degrees C
- Shelf life: Most users report using reconstituted vials within 4-6 weeks (longer stability than non-DAC version)
- Injection volume: Varies by concentration, typically 0.5-1 mL per weekly injection
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About CJC-1295 DAC
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.